Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
S. Spisak, D. Chen, P. Likasitwatanakul, P. Doan, Z. Li, P. Bala, L. Vizkeleti, P. De Silva, M. Giannakis, B. Wolpin, J. Qi, N. Sethi
bioRxiv · Jun 21, 2023 · PreprintCancer Biology
P. Sahgal, D. T. Patil, Z. Sztupinszki, V. Tisza, S. Spisak, B. Huffman, A. Prosz, H. Singh, J.-B. Lazaro, Z. Szallasi, J. M. Cleary, N. S. Sethi
The paper identifies DDR biomarkers and ploidy abnormalities in GEA that predict sensitivity to DDR inhibitors and premalignant progression.
bioRxiv · Mar 27, 2023 · PreprintCancer Biology
A. Prosz, H. Duan, V. Tisza, P. Sahgal, S. Topka, G. T.Klus, J. Borscok, Z. Sztupinszki, T. Hanlon, M. Diossy, L. Vizkeleti, D. R. Stormoen, I. Csabai, H. Pappot, J. Vijai, , Z. Szallasi
This paper identifies NER deficiency as a targetable vulnerability in ccRCC, showing that 10% of patients may respond to irofulven based on mutational signatures and PTGR1 expression.
bioRxiv · Feb 7, 2023Cancer Biology
L. Vizkeleti, C. Kiss, V. Tisza, A. Szigeti, A. Gellert, I. Csabai, L. S. Pongor, S. Spisak
This study investigates the epigenetic regulation of Septin9 variants in colorectal cancer, finding hypermethylation at the v2 promoter leads to alternative transcription and potential functional differences.
bioRxiv · Jan 31, 2023 · PreprintCancer Biology
A. Prosz, P. Sahgal, C. X. Morris, Z. Sztupinszki, J. Borcsok, M. Diossy, V. Tisza, S. Spisak, O. Rusz, I. Csabai, B. M. Huffman, H. Singh, J.-B. Lazaro, M. Cecchini, J. M. Cleary, , N. S. Sethi
This study identifies HR and NER deficiencies in gastric and esophageal adenocarcinomas and shows their responsiveness to platinum chemotherapy and PARP inhibitors.
bioRxiv · Jul 14, 2022 · PreprintCancer Biology
A. Nardone, X. Qui, A. Feiglin, X. Fu, S. Spisak, A. Feit, G. Cohen Feit, Y. Xie, A. Font-Tello, C. Guarducci, F. Hermida Prado, S. Syamala, K. Lim, M. Pun, M. Cornwell, , R. Jeselsohn
This study identifies a unique chromatin state in invasive lobular breast cancer (ILC) driven by FOXA1-ER axis, leading to tamoxifen resistance and poor outcomes.
bioRxiv · Mar 29, 2022Cancer Biology
M. Diossy, Z. Sztupinszki, J. Borcsok, M. Krzystanek, V. Tisza, S. Spisak, O. Rusz, J. Timar, I. Csabai, J. Moldvay, A. G. Pedersen, D. Szuts, Z. Szallasi
The paper identifies HRD-associated mutational signatures in lung cancer cases and links them to PARP inhibitor sensitivity and platinum response.
bioRxiv · Nov 28, 2019Cancer Biology
Z. Sztupinszki, M. Diossy, M. Krzystanek, J. Borcsok, M. Pomerantz, V. Tisza, S. Spisak, O. Rusz, I. Csabai, M. Freedman, Z. Szallasi
The paper identifies genomic aberration-based molecular signatures to detect homologous recombination deficiency in prostate cancer, finding that 5-8% of cases may benefit from PARP-inhibitor treatment.
bioRxiv · Jun 24, 2019 · PreprintCancer Biology